RecallRadar

FDA Drug recall D-0165-2025

Duloxetine Delayed-Release Capsules, 60 mg, a) 30 count blister cards (NDC 70518-0937-04), b) 30 count bottles (NDC 70518-0937-03), Rx only…

On 2025-01-01 the FDA classified a Class II recall of Duloxetine Delayed-Release Capsules, 60 mg, a) 30 count blister cards (NDC 70518-0937-04), b) 30 count bottles (NDC 70518-0937-03), Rx only… by Remedyrepack, citing CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0165-2025
ClassificationClass II
Statusongoing
Initiated2024-12-02
Published2025-01-01
Last updated2026-09-13 11:52 UTC
CompanyRemedyrepack
DistributionUS

Product

Duloxetine Delayed-Release Capsules, 60 mg, a) 30 count blister cards (NDC 70518-0937-04), b) 30 count bottles (NDC 70518-0937-03), Rx only, Source NDC 57237-0019-99, MFG: Rising Pharma, Inc., Allendale, NJ, Repackaged by: RemedyRepack Inc., Indiana, PA

Reason

CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.

Identifiers

code_infoa) NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025 b) NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0165-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.